JP2024508749A5 - - Google Patents

Info

Publication number
JP2024508749A5
JP2024508749A5 JP2023549562A JP2023549562A JP2024508749A5 JP 2024508749 A5 JP2024508749 A5 JP 2024508749A5 JP 2023549562 A JP2023549562 A JP 2023549562A JP 2023549562 A JP2023549562 A JP 2023549562A JP 2024508749 A5 JP2024508749 A5 JP 2024508749A5
Authority
JP
Japan
Prior art keywords
polypeptide
binding
bispecific molecule
antigen
trbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016423 external-priority patent/WO2022177889A1/en
Publication of JP2024508749A publication Critical patent/JP2024508749A/ja
Publication of JP2024508749A5 publication Critical patent/JP2024508749A5/ja
Pending legal-status Critical Current

Links

JP2023549562A 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料 Pending JP2024508749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (2)

Publication Number Publication Date
JP2024508749A JP2024508749A (ja) 2024-02-28
JP2024508749A5 true JP2024508749A5 (cg-RX-API-DMAC7.html) 2025-02-17

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549562A Pending JP2024508749A (ja) 2021-02-17 2022-02-15 クローンｔ細胞増殖を処置するための方法および材料

Country Status (7)

Country Link
US (1) US20240124608A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294841A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024508749A (cg-RX-API-DMAC7.html)
CN (1) CN117561277A (cg-RX-API-DMAC7.html)
AU (1) AU2022222679A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211203A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022177889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
WO2025007013A2 (en) * 2023-06-28 2025-01-02 The Johns Hopkins University Trbc targeting antibody-drug conjugates
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3241561T3 (da) 2014-03-05 2025-06-30 Autolus Ltd Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Similar Documents

Publication Publication Date Title
JP2024508749A5 (cg-RX-API-DMAC7.html)
JP2023551535A5 (cg-RX-API-DMAC7.html)
JP2021530987A5 (cg-RX-API-DMAC7.html)
JP2022061993A5 (cg-RX-API-DMAC7.html)
US20210355217A1 (en) T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibody
JP2020537644A5 (cg-RX-API-DMAC7.html)
CN110741018A (zh) 抗原结合结构域
JP2020529830A5 (cg-RX-API-DMAC7.html)
JP2023526774A5 (cg-RX-API-DMAC7.html)
JP2021523122A5 (cg-RX-API-DMAC7.html)
JP2023519099A5 (cg-RX-API-DMAC7.html)
JP2021512107A5 (cg-RX-API-DMAC7.html)
JP2022544825A5 (cg-RX-API-DMAC7.html)
JP2023522857A5 (cg-RX-API-DMAC7.html)
Kamakura et al. Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation
KR20230086674A (ko) 파킨슨 질환의 치료
JP7704748B2 (ja) 逐次抗ｃｄ１９治療
JP2024508749A (ja) クローンｔ細胞増殖を処置するための方法および材料
JP2021524451A5 (cg-RX-API-DMAC7.html)
HUE026740T2 (en) Treatment of Multiple Sclerosis (MS) with Campath-1H
JP2024513054A5 (cg-RX-API-DMAC7.html)
Vartzelis et al. Rituximab as rescue therapy for aggressive pediatric multiple sclerosis
Dinov et al. Current and emerging therapies for autoimmune encephalitis
Hewitt et al. Overlap of generalized morphea and eosinophilic fasciitis after recreational exposure to epoxy resin
JP2023540618A5 (cg-RX-API-DMAC7.html)